Literature DB >> 10392958

Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.

B D Johnson1, E E Becker, R L Truitt.   

Abstract

Infusions of donor leukocytes have been given to allogeneic bone marrow recipients after transplant to treat leukemia relapse. Treatment with these delayed infusions of donor cells has been called delayed or donor leukocyte infusion (DLI). While graft-vs.-host disease (GVHD) has typically been less severe than expected after DLI, it still remains a significant risk factor. Recently, we used a full major histocompatibility complex (MHC)-mismatched model (C57BL/6 into AKR) to determine how increased immunogenetic disparity affects GVH and graft-vs.-leukemia (GVL) reactions after DLI. In contrast to an MHC-matched model (B10.BR into AKR), GVHD was still observed when MHC-mismatched donor T cells were infused 3 weeks posttransplant. Limiting dilution analysis was used to determine the frequency of alloreactive cytotoxic T lymphocytes (CTL) and interleukin (IL)-2-secreting T helper cells in the spleens of MHC-mismatched recipients 7 days after DLI treatment. GVHD correlated with elevated frequencies of alloreactive T-helper cells. One strategy for reducing the severity of GVHD after DLI is the selective administration of CD4 or CD8 T-subsets. Delayed infusion of purified T-subsets 3 weeks posttransplant resulted in significantly less GVHD than infusion of a mixture of the two subsets. No GVH-associated mortality was observed after DLI with purified donor CD4+ T cells. In GVL studies, MHC-mismatched CD8+ T cells were the most potent antitumor effectors against an acute T cell leukemia. The GVL effect of MHC-mismatched T-subsets was compared with that of MHC-matched subsets. When naive MHC-matched cells were given as DLI, depletion of either T-subset eliminated the GVL effect. CD8+ T cells from MHC-matched donors primed against host alloantigens, however, mediated a CD4 (T-helper)-independent GVL reaction. Together, these results suggest that administration of T-subsets can significantly reduce GVHD after DLI without loss of the beneficial GVL effect.

Entities:  

Mesh:

Year:  1999        PMID: 10392958     DOI: 10.1053/bbmt.1999.v5.pm10392958

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

1.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

2.  Donor-derived CD4(+)/CCR7(+) T-cell partial selective depletion does not alter acquired anti-infective immunity.

Authors:  B Choufi; J Trauet; S Thiant; M Labalette; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

3.  Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.

Authors:  James N Kochenderfer; Jessica L Simpson; Christopher D Chien; Ronald E Gress
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 4.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

5.  Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease.

Authors:  Yi Zhang; Jean-Pierre Louboutin; Jiang Zhu; Adam J Rivera; Stephen G Emerson
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

6.  Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice.

Authors:  Dapeng Wang; Yu Yu; Kelley Haarberg; Jianing Fu; Kane Kaosaard; Srinivas Nagaraj; Claudio Anasetti; Dmitry Gabrilovich; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-30       Impact factor: 5.742

Review 7.  Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.

Authors:  Carrie Gibbons; Megan Sykes
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 8.  Reconstructing immunity after allogeneic transplantation.

Authors:  Cynthia R Giver; Jian-Ming Li; Mohammad S Hossain; Sagar Lonial; Edmund K Waller
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

9.  Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.

Authors:  Nancy M Hardy; Frances Hakim; Seth M Steinberg; Michael Krumlauf; Romana Cvitkovic; Rebecca Babb; Jeanne Odom; Daniel H Fowler; Ronald E Gress; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-16       Impact factor: 5.742

10.  Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.

Authors:  Panagiotis Tsirigotis; Konstantinos Gkirkas; Vassiliki Kitsiou; Spiros Chondropoulos; Theofilos Athanassiades; Thomas Thomopoulos; Alexandra Tsirogianni; Maria Stamouli; Aggeliki Karagiannidi; Nikolaos Siafakas; Vassiliki Pappa; Arnon Nagler
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.